Brief: Vertex Signs LOI With pCPA For ALYFTREK In Cystic Fibrosis Treatment
06/07/2026 16:27
BRIEF-Vertex Signs LOI With pCPA For ALYFTREK In Cystic Fibrosis Treatment July 6 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
VERTEX SIGNS LETTER OF INTENT (LOI) WITH THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR ALYFTREK FOR THE TREATMENT OF CYSTIC FIBROSIS
VERTEX PHARMACEUTICALS - TO INITIATE DISCUSSIONS FOR PUBLIC LISTING OF ALYFTREK IN CANADA
Source text: ID:nCNWrQLg6a
Further company coverage: VRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria